Shots:

• The P-II POC study assess safety and efficacy of ANG-3777 (2.0 mg/kg- IV) + SOC vs PBO + SOC in ~100 patients in a ratio (1:1) hospitalized with confirmed COVID-19 pneumonia with 1EPs as the proportion of patients alive- without the need for mechanical ventilation and renal replacement therapy (on an ongoing basis) @28day
• Following the success of the P-II study- the company plans to submit an IND for the therapy in the US. Additionally- Angion is conducting a P-III study of ANG-3777 to improve kidney function and reduce the severity of transplant-associated AKI in patients showing evidence of early kidney dysfunction and in a P-II clinical trial for the treatment of AKI associated with cardiac surgery involving cardiopulmonary bypass
• ANG-3777 is designed to mimic the biological activity of hepatocyte growth factor (HGF)- which activates the c-Met cascade of pathways involved in tissue repair and organ repair

Click here to read full press release/ article | Ref: PRNewswire | Image: Angion